HUTCHMED (China) Limited HCM

Company Overview

HUTCHMED (China) Limited (HCM) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates primarily within the oncology and immunology segments of the pharmaceutical industry, with an emphasis on innovative small-molecule and biologic drugs. Its core revenue drivers are proprietary oncology products approved in Mainland China, alongside milestone payments and royalties from global licensing partnerships.

The company serves patients, hospitals, and healthcare systems, primarily in China, with expanding reach into the United States, Europe, and other international markets through strategic partners. HUTCHMED’s positioning is differentiated by its fully integrated model that combines in-house drug discovery, clinical development, regulatory expertise, and commercial capabilities within China, complemented by global collaborations. The company was founded in 2000 as Chi-Med and later rebranded as HUTCHMED, reflecting its evolution from a traditional pharmaceutical business into an innovation-driven biopharmaceutical enterprise backed by the Hutchison Group.